Patents by Inventor Marcos M. Pires

Marcos M. Pires has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8575311
    Abstract: Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes, as drug delivery vehicles and in delivering populations of cells to a site of disease or injury.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: November 5, 2013
    Assignee: Purdue Research Foundation
    Inventors: Jean A Chmielewski, Marcos M Pires, David E Przybyla
  • Publication number: 20110081324
    Abstract: Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes, as drug delivery vehicles and in delivering populations of cells to a site of disease or injury.
    Type: Application
    Filed: May 15, 2009
    Publication date: April 7, 2011
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Jean A Chmielewski, Marcos M. Pires, David E. Przybyla
  • Publication number: 20100068786
    Abstract: A method for inhibiting therapeutic drug resistance within a cell over-expressing a membrane protein is provided. The method comprises synthesizing a dimeric prodrug inhibitor of a monomeric therapeutic agent; administering the dimeric prodrug inhibitor to the membrane protein together with the monomeric therapeutic agent; and occupying at least one substrate binding site of the membrane protein with the synthesized dimeric prodrug to allow the monomeric therapeutic agent to accumulate within the cell. The dimeric prodrug inhibitor contains a crosslinking agent that is adapted to breakdown under reducing conditions within the cytosol of the cell to cause the dimeric prodrug to revert back to a form equivalent to the monomeric therapeutic agent.
    Type: Application
    Filed: September 16, 2009
    Publication date: March 18, 2010
    Inventors: Jean A. Chmielewski, Christine A. Hrycyna, Marcos M. Pires